Stay updated on Measles Virus Systemic Oncolytic Clinical Trial
Sign up to get notified when there's something new on the Measles Virus Systemic Oncolytic Clinical Trial page.

Latest updates to the Measles Virus Systemic Oncolytic Clinical Trial page
- Check2 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and the NIH Clinical Center's operating status, along with related topic tags (Multiple myeloma, MedlinePlus Genetics) and a revision update from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check9 days agoChange DetectedAdded a glossary and QC-related metadata (Last Update Submitted that Met QC Criteria) plus a revision tag (Revision: v3.4.0). Removed or altered several non-core related topics and terms (e.g., Multiple myeloma, MedlinePlus Genetics) and minor capitalization changes.SummaryDifference0.4%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 with no impact on study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check30 days agoChange DetectedMedlinePlus Genetics has been added to the related topics, and Multiple myeloma is now listed as a related topic. The primary trial content remains unchanged.SummaryDifference0.2%

- Check37 days agoChange DetectedRemoved the 'Multiple myeloma' condition tag and the related topic 'MedlinePlus Genetics' from the page's keyword/related topics section.SummaryDifference0.2%

- Check44 days agoChange DetectedFooter/navigation updates add a 'Locations' header and an 'Arkansas' entry, remove the 'HHS Vulnerability Disclosure' and 'Arkansas Locations' items, and update the page revision to v3.3.3.SummaryDifference0.3%

Stay in the know with updates to Measles Virus Systemic Oncolytic Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Measles Virus Systemic Oncolytic Clinical Trial page.